

## Receptor-mediated Modulation of Human Monocyte, Neutrophil, Lymphocyte, and Platelet Function by Phorbol Diesters

Bonnie J. Goodwin

*J Clin Invest.* 1982;70(4):699-706. <https://doi.org/10.1172/JCI110665>.

### Research Article

The tumor promoting phorbol diesters elicit a variety of responses from normal and leukemic blood cells in vitro by apparently interacting with cellular receptors. The biologically active ligand [20-<sup>3</sup>H] phorbol 12,13-dibutyrate (<sup>3</sup>H]PDBu) bound specifically to intact human lymphocytes, monocytes, polymorphonuclear leukocytes (PMN), and platelets, but not to erythrocytes. Binding, which was comparable for all four blood cell types, occurred rapidly at 23° and 37°C, reaching a maximum by 20-30 min usually followed by a 30-40% decrease in cell associated radioactivity over the next 30-60 min. The time course for binding was temperature dependent with equilibrium binding occurring after 120-150 min at 4°C, with no subsequent loss of cell-associated radioactivity at this temperature. Bound [<sup>3</sup>H]PDBu could be eluted by addition of unlabeled PDBu. Scatchard analysis of data from 4°C binding studies revealed linear plots with high affinity receptors in these cell types with dissociation constants and receptors per cell of 60 nM and  $7.8 \times 10^5$ /cell for lymphocytes, 51 nM and  $15.5 \times 10^5$ /cell for monocytes, 38 nM and  $4.0 \times 10^5$ /cell for PMN, and 19 nM and  $2.9 \times 10^4$ /cell for platelets. Structure-activity studies using unlabeled phorbol-related compounds demonstrated a close correlation between their abilities to inhibit binding of [<sup>3</sup>H]PDBu to cells and their abilities to induce cellular responses (monocyte and PMN H<sub>2</sub>O<sub>2</sub> secretion, lymphocyte <sup>3</sup>HTdR incorporation, and platelet tritiated [...])

Find the latest version:

<https://jci.me/110665/pdf>



# Receptor-mediated Modulation of Human Monocyte, Neutrophil, Lymphocyte, and Platelet Function by Phorbol Diesters

BONNIE J. GOODWIN, *Department of Medicine, Division of Hematology-Oncology, Duke University Medical Center, Durham, North Carolina 27710*

J. BRICE WEINBERG, *Department of Medicine, Division of Hematology-Oncology, Veterans Administration Medical Center and Duke University Medical Center, Durham, North Carolina 27705*

**ABSTRACT** The tumor promoting phorbol diesters elicit a variety of responses from normal and leukemic blood cells in vitro by apparently interacting with cellular receptors. The biologically active ligand [20-<sup>3</sup>H] phorbol 12,13-dibutyrate ([<sup>3</sup>H]PDBu) bound specifically to intact human lymphocytes, monocytes, polymorphonuclear leukocytes (PMN), and platelets, but not to erythrocytes. Binding, which was comparable for all four blood cell types, occurred rapidly at 23° and 37°C, reaching a maximum by 20–30 min usually followed by a 30–40% decrease in cell associated radioactivity over the next 30–60 min. The time course for binding was temperature dependent with equilibrium binding occurring after 120–150 min at 4°C, with no subsequent loss of cell-associated radioactivity at this temperature. Bound [<sup>3</sup>H]PDBu could be eluted by addition of unlabeled PDBu. Scatchard analysis of data from 4°C binding studies revealed linear plots with high affinity receptors in these cell types with dissociation constants and receptors per cell of 60 nM and  $7.8 \times 10^5$ /cell for lymphocytes, 51 nM and  $15.5 \times 10^5$ /cell for monocytes, 38 nM and  $4.0 \times 10^5$ /cell for PMN, and 19 nM and  $2.9 \times 10^4$ /cell for platelets. Structure-activity studies using unlabeled phorbol-related compounds demonstrated a close correlation between their abilities to inhibit binding of [<sup>3</sup>H]PDBu to cells and their abilities to induce cellular responses (monocyte and PMN H<sub>2</sub>O<sub>2</sub> secretion, lymphocyte <sup>3</sup>HTdR incorporation, and platelet tritiated serotonin release); phorbol and 4- $\alpha$  phorbol were inactive while phorbol 12-myristate 13-acetate (PMA), PDBu, mezerein, and phorbol 12,13-diacetate (in de-

creasing order of potency) inhibited [<sup>3</sup>H]PDBu binding and elicited the various responses. Thus, these high affinity, specific receptors for the phorbol diesters, present on monocytes, lymphocytes, PMN, and platelets, mediate the pleiotypic effects induced by these ligands.

## INTRODUCTION

Tumor promoting agents are substances, which although noncarcinogenic themselves, cause tumor formation when applied repeatedly to mouse skin that has been previously treated with a subthreshold dose of a carcinogen. The most potent promoters in the mouse skin system are esters of the tetracyclic diterpene phorbol (1, 2). The phorbol esters, in vitro, cause a variety of biological responses in many different cell types, including normal and leukemic blood cells (3–6). These include stimulation of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and superoxide anion (O<sub>2</sub><sup>-</sup>) production by polymorphonuclear leukocytes (PMN)<sup>1</sup> and monocytes (7–9), aggregation and serotonin release by platelets (10, 11), and mitogenesis in lymphocytes (12, 13).

The phorbol esters bind in a specific, saturable, reversible fashion to a variety of cells and cell particulate fractions (14–17). Their binding affinities generally are comparable to their abilities to induce cellular changes in vitro, such as the loss of surface fibronectin from

<sup>1</sup> *Abbreviations used in this paper:* DMM, Dulbecco's Modified Eagle Medium; [<sup>3</sup>H]5HT, tritiated hydroxytryptamine binoxalate 5-[1,2-<sup>3</sup>H(N)]-serotonin; [<sup>3</sup>H]PDBu, 20-<sup>3</sup>H phorbol 12,13-dibutyrate; MZ, mezerein; PDA, phorbol 12,13 diacetate; PHR, phorbol; 4 $\alpha$ -PHR, 4 $\alpha$ -phorbol; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonuclear leukocyte; PRP, platelet-rich plasma.

Received for publication 26 March 1982 and in revised form 9 June 1982.

chicken embryo fibroblasts (14) and the production of interleukin 2 by lymphocytes (17). Likewise, the binding affinities of the phorbol esters seem to parallel their tumor-promoting potencies in the mouse skin model (14–18). It thus appears that these substances initiate their effects by binding to a specific cellular receptor.

In this study, using [ $^3\text{H}$ ] phorbol 12,13-dibutyrate ([ $^3\text{H}$ ]PDBu), we demonstrate and characterize the specific binding of this labeled phorbol ester to human PMN, monocytes, lymphocytes, and platelets. In addition, we show that the binding affinities ( $K_d$ ) of [ $^3\text{H}$ ]PDBu and the inhibitory constants ( $K_i$ ) of related unlabeled compounds, correlate well with the doses required to elicit 50% of the maximal level of selected responses by these blood cells (ED50).

## METHODS

Dulbecco's modified Eagle medium (DMM, Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) was formulated with endotoxin-free water and supplemented with 100 U/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin, 20 mM Hepes, 1 mg/ml dextrose, and sterilized by filtration. Ficoll-sodium diatrizoate, specific gravity 1.077 (Histopaque 1077), dextran (mol wt = 500,000), horseradish peroxidase (type II), and superoxide dismutase were obtained from Sigma Chemical Co., St. Louis, MO. Gey's balanced salt solution with 2% bovalbumin (Gey's-BSA) was from Flow Laboratories, Inc., Rockville, MD. Polyvinyl pyrrolidone-coated silica (Percoll) and Sepharose 2B were obtained from Pharmacia Fine Chemicals, Uppsala, Sweden. [ $^3\text{H}$ ]PDBu, as well as tritiated hydroxytryptamine binoxalate (5-[1,2- $^3\text{H}$ (N)]-serotonin) ([ $^3\text{H}$ ]5HT) and thymidine ([methyl- $^3\text{H}$ ]thymidine) were purchased from New England Nuclear, Boston, MA. Phorbol (PHR), phorbol 12-myristate 13-acetate (PMA), phorbol 12,13 dicetate (PDA), 4 $\alpha$ -phorbol (4 $\alpha$ -PHR), and mezerein (MZ) were from P-L Biochemicals, Inc., Milwaukee, WI.

**Isolation of blood cells.** Peripheral blood was obtained from normal donors after their informed consent according to a protocol approved by the Duke University Clinical Investigation Committee. Monocytes and lymphocytes were isolated from heparinized blood (10 U/ml), as described (19), using sequential Ficoll-sodium diatrizoate separation and discontinuous Percoll gradient centrifugation. Following the wash steps, the cells from the monocyte and lymphocyte bands were suspended in DMM for use in experiments. Based on Wright's and nonspecific esterase staining, the monocytes and lymphocytes were >85% pure. PMN were separated from heparinized blood by a described method (20) using Ficoll-sodium diatrizoate sedimentation for removal of mononuclear cells followed by dextran (3%) sedimentation of the remaining erythrocytes and buffy coat. There was <1% contamination by mononuclear cells and hypotonic lysis removed remaining erythrocytes. PMN were suspended in DMM for most experiments. Platelets were obtained using a modification of the gel filtration method of Tangen (21). Column buffer consisted of 0.137 M NaCl, 0.0056 M dextrose, 0.0027 M KCl, 0.00042 M Na H<sub>2</sub>PO<sub>4</sub>, 0.012 M NaHCO<sub>3</sub>, and 0.00011 M EDTA. Before experiments, 1 part 0.025 M CaCl<sub>2</sub> was added to 9 parts buffer and platelets. Erythrocytes were obtained after Ficoll-sodium diatrizoate sedimentation of heparinized blood from the cells in the lowermost portion of the tubes. They were washed and found to be leukocyte free and suspended to DMM for experiments.

**Binding assays.** The standard binding assay was done in 5 ml polypropylene tubes (Walter Sarstedt, Inc., Princeton, NJ) containing a final volume of 0.2 ml.  $5\text{--}10 \times 10^5$  blood cells (or  $1 \times 10^7$  for platelet experiments) in 0.1 ml of DMM for PMN, lymphocyte, monocyte, and erythrocyte assays, or 0.1 ml of platelet buffer for platelet assays were added to each tube, and 0.1 ml Gey's-BSA containing the experimental concentration of [ $^3\text{H}$ ]PDBu or [ $^3\text{H}$ ]PDBu plus potential inhibitors of binding was added. To determine nonspecific binding, all experiments were done in the presence and absence of 30  $\mu\text{M}$  unlabeled PDBu. All results are presented as specific binding (that is, the difference between [ $^3\text{H}$ ]PDBu bound in the presence and absence of this excess unlabeled PDBu). Binding assays were carried out in triplicate and cells and additives were allowed to reach the experimental temperature [4°, 23°, or 37°C] before being placed together. Following incubation at a specific temperature for a desired length of time, 4 ml of cold assay wash buffer (19) was added to each tube and the cells and solution aspirated from the tubes with a semiautomated sample harvester (Otto Hiller Co., Madison, WI) using glass fiber filter paper (Whatman 5679, grade 943AH, Whatman Inc., Paper Div., Clifton, NJ). Each tube was then washed with an additional 4 ml of cold assay wash buffer. The filters were counted in Aquasol-2 (New England Nuclear) using a Packard Tricarb Scintillation Counter (3375, Packard Instrument Co., Inc., Downers Grove, IL).

**Platelet serotonin release.** Platelet serotonin release was measured with a modification of a described technique (22). Platelet-rich plasma (PRP) was incubated with [ $^3\text{H}$ ]5HT (1  $\mu\text{Ci}/\text{ml}$  PRP) at 37°C for 30 min before gel filtration over Sepharose 2B. 0.45 ml of gel-filtered, [ $^3\text{H}$ ]5HT-labeled platelets ( $1\text{--}2 \times 10^8$  platelets/ml) in platelet column buffer were incubated with 0.05 ml of the potential stimulator of serotonin release in platelet column buffer ( $10 \times$  final experimental concentration) or 0.05 ml platelet column buffer (for a blank) at 37°C for 15 min. 0.05 ml of 50 mM cold EDTA was added, and the samples were centrifuged for 5 min in a Beckman microfuge (Beckman Instruments, Inc., Fullerton, CA). 0.2 ml of supernatant was removed and radioactivity counted in Aquasol-2. 0.2 ml of a lysate consisting of 0.45 ml [ $^3\text{H}$ ]5HT serotonin-labeled platelets, 0.05 ml 50 mM EDTA, and 0.05 ml 20% Triton X-100 was also counted. Percent release was calculated using the formula: [(counts per minute in sample supernatant - counts per minute in blank)  $\div$  (counts per minute in lysate - counts per minute in blank)]  $\times$  100.

**Hydrogen peroxide production.** This assay was done in 96 chamber microtitre plates (Microtest II, No. 3040, Falcon Labware, Div. Becton-Dickinson & Co., Oxnard, CA) using a modification of a described method (23).  $1\text{--}2 \times 10^5$  monocytes or PMN were incubated in a total volume of 0.2 ml assay buffer containing 1 mg/ml glucose, 19 U/ml horseradish peroxidase, and 2 g/liter phenol red plus varying concentrations of potential stimulants for H<sub>2</sub>O<sub>2</sub> release for 1 h at 37°C. The plates were then read using a Multiskan automatic eight-channel photometer (Flow Laboratories, Inc.) at 600 nm after alkalization with 0.01 ml 1 N NaOH. H<sub>2</sub>O<sub>2</sub> production was calculated by construction of a standard curve with exogenous H<sub>2</sub>O<sub>2</sub>.

**Thymidine incorporation.** Lymphocytes ( $3\text{--}5 \times 10^5/\text{well}$ ) were cultured in DMM with or without serum in the presence of various concentrations of potential stimulators of thymidine incorporation for 24 h in microtitre plates. 1  $\mu\text{Ci}$  of tritiated thymidine was added per microtitre chamber and the cells allowed to incubate at 37°C for an additional 24 h. At the end of this time, the cells were harvested as described




FIGURE 1 Representative time courses of specific [ $^3\text{H}$ ]PDBu binding to intact human PMN (A), monocytes (B), lymphocytes (C), and platelets (D) at 4°C ( $\Delta$ ), 23°C ( $\circ$ ), and 37°C ( $\bullet$ ). Specific binding was measured using 50 nM [ $^3\text{H}$ ]PDBu and 30  $\mu\text{M}$  unlabeled PDBu. Each point is the mean of three replicates and results are expressed as percentage of maximum binding occurring at that temperature. SEM for the triplicates ranged from 0.5 to 5.8%. Similar results to those displayed in this figure were seen in two other separate experiments using PMN, monocytes, and lymphocytes and in one other using platelets.

for binding assays and cell associated radioactivity counted in Aquasol-2.

## RESULTS

**General characteristics of [ $^3\text{H}$ ]PDBu binding.** There was specific binding of [ $^3\text{H}$ ]PDBu to PMN, lymphocytes, monocytes, and platelets, but as previously reported (15), erythrocytes did not specifically bind the [ $^3\text{H}$ ]PDBu. Nonspecific binding of the ligand was generally linear with respect to the concentration of [ $^3\text{H}$ ]PDBu added and at maximum, accounted for <30% of the total [ $^3\text{H}$ ]PDBu bound or <1% of the [ $^3\text{H}$ ]PDBu added. The time course for the specific binding of [ $^3\text{H}$ ]PDBu varied with temperature (4°, 23°, and 37°C) but was generally similar for PMN, lymphocytes, monocytes, and platelets, at a given temperature (representative time courses are seen in Fig. 1). Binding was rapid at 23° and 37°C, reaching a maximum by 1–5 min at 37°C and by 20–30 min at 23°C. This was followed by a 30–40% decline in cell-associated radioactivity over the next 2–3 h in all instances except for platelets at 23°C. While seen in all experiments, the rate of this decline in cell-associated radioactivity was somewhat variable. Dissociated radioactivity was found in the media, and analysis by thin-layer chromatography after 3 h showed no degradation of the [ $^3\text{H}$ ]PDBu.<sup>2</sup> At 4°C there was a slower increase in spe-

cific binding of [ $^3\text{H}$ ]PDBu with time, reaching a maximum by 120–150 min. As opposed to experiments done at 23° or 37°C, where a stable plateau of binding was not achieved, no subsequent loss of bound material was noted after maximum binding had been reached at 4°C.

Comparable to the rate of association of the ligand, the rate of dissociation of cell-associated radioactivity, following the addition of excess unlabeled PDBu, was rapid at 23°C, with <10% of the initial radioactivity remaining after 15 min (Fig. 2). The dissociation was much slower at 4°C, paralleling the slower rate of binding at this temperature.

To further characterize [ $^3\text{H}$ ]PDBu binding as a function of ligand concentration, binding assays were done at 4°C for 2–3 h. Mean data for specific binding to lymphocytes, monocytes, PMN, and platelets are presented in Fig. 3. Scatchard analysis of the binding data revealed linear curves for all of these blood cells suggesting the presence of one class of binding site in each case (Fig. 4). The  $K_d$  were similar for all four cell types, however, the calculated number of binding sites per cell was more variable. With the lack of development of steady-state binding in the time course experiments at 23°C and 37°C, it was felt that valid Scatchard analysis of [ $^3\text{H}$ ]PDBu binding could be made only at 4°C. Mean values for  $K_d$  and number of sites per cell for the blood cells at this temperature are given in Table I.

**Specificity of binding.** The relative potency of the

<sup>2</sup> Weinberg, J. B., and B. J. Goodwin. Manuscript in preparation.




FIGURE 2 Dissociation of specifically bound  $[^3\text{H}]\text{PDBu}$  from monocytes ( $\circ$ ) and lymphocytes ( $\Delta$ ) at  $4^\circ$  and  $23^\circ\text{C}$  following the addition of excess ( $20\ \mu\text{M}$ ) unlabeled PDBu. Binding was done for 30 min at  $23^\circ\text{C}$  and for 60 min at  $4^\circ\text{C}$  using  $50\ \text{nM}$   $[^3\text{H}]\text{PDBu}$  in the absence and presence of  $30\ \mu\text{M}$  unlabeled PDBu before the addition of the excess unlabeled PDBu at time 0. The points and bars represent the mean of three replicates  $\pm 1$  SEM.

phorbol esters and related compounds to promote tumor formation in vivo and to cause cellular changes in vitro is highly dependent on their structure (24). In other cell types, the  $K_i$  for  $[^3\text{H}]\text{PDBu}$  binding of various phorbol derivatives correlate well with their potency in evoking these in vivo and in vitro changes. The inhibition of  $[^3\text{H}]\text{PDBu}$  binding to lymphocytes, monocytes, and PMN by various phorbol esters and MZ was examined. In these cell types, binding was inhibited by PDA, PMA, PDBu, and MZ but not by the PHR (Fig. 5). The order of potency of these compounds for inhibition of  $[^3\text{H}]\text{PDBu}$  binding paralleled their biological potency as tumor promoters in the mouse skin model (25). That is, PMA was the most potent inhibitor of binding followed by PDBu




FIGURE 3 Representative equilibrium specific  $[^3\text{H}]\text{PDBu}$  binding to intact human monocytes ( $\bullet$ ); lymphocytes ( $\Delta$ ), PMN ( $\blacktriangle$ ), platelets ( $\circ$ ), and erythrocytes ( $\square$ ) as a function of ligand concentration. Incubation was at  $4^\circ\text{C}$  in the absence and presence of  $30\ \mu\text{M}$  unlabeled PDBu for 2 h. Each point represents the mean of triplicates and the standard errors ranged from 1.2 to 6.6% of the mean.

and then MZ and PDA, while PHR, biologically inactive as a promoter, was not inhibitory of  $[^3\text{H}]\text{PDBu}$  binding. The apparent  $K_i$  for this inhibition are shown in Table II.

**Correlation of  $[^3\text{H}]\text{PDBu}$  binding with cellular functions.** Lymphocytes cultured with increasing concentrations of PMA showed a dose-dependent rise in tritiated thymidine incorporation with an  $\text{ED}_{50}$  of  $6\ \text{nM}$  (Fig. 6A). There was a similar dose-dependent increase in stimulation index with increasing PDBu concentrations but the  $\text{ED}_{50}$  ( $40\ \text{nM}$ ) was higher than that for PMA. This  $\text{ED}_{50}$  value for PDBu stimulation is similar to the  $K_d$  of  $60\ \text{nM}$  for  $[^3\text{H}]\text{PDBu}$  binding to lymphocytes. Unlike the biologically active phorbol esters, the nonpromoting substance  $4\alpha\text{-PHR}$  caused no increase in stimulation index with escalating concentrations. At the higher concentrations of PMA and PDBu, in the absence of serum, the stimulation indices diminished, suggesting toxicity to the cells. Experiments done in the presence of 10% fetal bovine serum showed greater overall stimulation of thymidine incorporation and substantially eliminated this apparent toxic effect of the higher phorbol ester concentrations (Fig. 6B). This effect of serum, in addition to its more general beneficial effect on cultured cell growth, could be related to the binding of PMA and PDBu to a protein in the serum, recently characterized by Shoyab and Todaro (27), which binds  $[^3\text{H}]\text{PDBu}$  and competitively inhibits the binding of  $[^3\text{H}]\text{PDBu}$  to its specific cellular receptors.  $\text{ED}_{50}$  were higher than those in the absence of serum ( $420\ \text{nM}$  for PMA and  $1,000\ \text{nM}$  for PDBu). Once again,  $4\alpha\text{-PHR}$  caused no increase in stimulation index.




FIGURE 4 Scatchard plot of equilibrium  $[^3\text{H}]\text{PDBu}$  binding data presented in Fig. 2 for human monocytes ( $\bullet$ ); lymphocytes ( $\Delta$ ), PMN ( $\blacktriangle$ ), and platelets ( $\circ$ ). The lines were determined by linear regression with  $r = 0.98$  (monocytes),  $r = 0.98$  (lymphocytes),  $r = 0.98$  (PMN), and  $r = 0.96$  (platelets).

TABLE I  
Mean  $K_d$  and Sites/Cell for [ $^3$ H]PDBu Binding to Normal Human Blood Cells at 4°C

Cell type	$K_d$	Mean number sites per cell
Monocytes	51±6 nM ( $n = 5$ )	$15.5 \times 10^5 \pm 4.3 \times 10^5$
Lymphocytes	60±4 nM ( $n = 4$ )	$7.8 \times 10^5 \pm 2.7 \times 10^5$
PMN	38±9 nM ( $n = 2$ )	$4.0 \times 10^5 \pm 1.1 \times 10^5$
Platelets	19 nM ( $n = 1$ )	$2.9 \times 10^4$
Erythrocytes	* ( $n = 2$ )	*

\* No detectable binding.

TABLE II  
 $K_i$  for Inhibition of [ $^3$ H]PDBu Binding of Phorbol-related Compounds

Inhibiting substance	Cell type		
	PMN	Lymphocytes	Monocytes
PMA	75 nM	18 nM	65 nM
PDBu	100 nM	60 nM	165 nM
MZ	1,000 nM	200 nM	350 nM
PDA	30 $\mu$ M	4 $\mu$ M	5 $\mu$ M
PHR	*	*	*

\* No inhibition noted.

PDBu stimulated the production of  $H_2O_2$  by human monocytes and PMN in a dose-dependent fashion with an ED50 of 42 nM for both these cell types. This ED50 correlated well with the  $K_d$  of [ $^3$ H]PDBu binding to monocytes (51 nM) and PMN (38 nM). PMA, PDA, and mezerein likewise caused increased  $H_2O_2$  production by monocytes and PMN (Fig. 7) with ED50 as displayed in Table III, while the biologically inactive compounds 4 $\alpha$ -PHR and PHR caused no increased release. Although MZ caused a higher maximum  $H_2O_2$  secretion by monocytes in Fig. 7, this was not the case in other comparable experiments and in experiments using mouse peritoneal macrophages (data not shown).

PDBu stimulated the release of [ $^3$ H]5HT from platelets in a dose-dependent fashion (Fig. 8). The ED50 of 18 nM correlated closely with the  $K_d$  for [ $^3$ H]PDBu binding to platelets of 19 nM. Likewise, PMA, the more potent tumor-promoting substance, caused a dose-dependent increase in [ $^3$ H]5HT release, but with a lower ED50 of

3 nM. PHR and 4  $\alpha$ -PHR caused no increase in [ $^3$ H]5HT release.

## DISCUSSION

Recent studies support the hypothesis that the primary interaction of the phorbol esters is with specific binding sites on the cell surface, and that they may mediate at least some of their pleiotypic cellular effects via these receptors (14–18). In the present report, using [ $^3$ H]PDBu as a ligand, we have provided evidence that normal human blood lymphocytes, monocytes, PMN, and platelets have specific receptors for [ $^3$ H]PDBu and the related phorbol esters, while erythrocytes do not. In addition, we demonstrated the close correlation between the affinities of the phorbol esters for these receptors and their ability to evoke the biological responses of  $H_2O_2$  generation by PMN and monocytes,




FIGURE 5 Dose-response curves for inhibition of specific [ $^3$ H]PDBu binding to PMN (A), monocytes (B), and lymphocytes (C) by phorbol related compounds [PMA ( $\square$ ), PDBu ( $\circ$ ), MZ ( $\bullet$ ), PDA ( $\Delta$ ), and PHR ( $\blacktriangle$ )]. In each experiment, specific binding of [ $^3$ H]PDBu in the presence of the potential inhibitor is expressed as a percentage of the specific binding in the absence of the competing ligand. Each point represents the value obtained from the mean of three replicates, and the SEM for the triplicates was <5%. All potential inhibitors were tested simultaneously using all three blood cell types obtained from the same donor. Similar results were obtained in three separate experiments.  $K_i$  (Table II) were calculated as described (26).




FIGURE 6 Tritiated thymidine incorporation by lymphocytes cultured with phorbol-related compounds in the absence (A) and presence (B) of 10% fetal bovine serum. Data are expressed as stimulation index (that is, sample counts per minute  $\div$  control counts per minute). Each point represents the mean of triplicates  $\pm$  1 SEM. This data is representative of two comparable experiments.

thymidine incorporation by lymphocytes, and serotonin release by platelets. Lehrer and Cohen (8) in studies using [ $^3$ H]PMA and [ $^3$ H]PDBu demonstrated PMN phorbol diester receptors comparable to those we describe here. They showed that the extent of PMN superoxide production in response to PMA was directly proportional to the fractional occupancy of the receptor by PMA.

Rapid binding of [ $^3$ H]PDBu to all four cell types occurred at 23° and 37°C, followed by a loss of this cell-associated radioactivity with time (except in the platelet experiments done at 23°C). Binding was slower at 4°C and in most cases reached a maximum plateau level that was stable. These results are consistent with the observations of Solanki and Slaga (28, 29) in mouse epidermal and HL60 cells and Sando et al. (17) with human lymphocytes. The cause of this loss of [ $^3$ H]PDBu binding is unclear but could result from conformational changes in the binding site with elution of the ligand from the cells. As a steady state of binding was achieved only at 4°C, valid Scatchard

analysis of [ $^3$ H]PDBu binding data could be made only at this temperature. This analysis was linear for all cell types, indicative of one population of receptor. This is consistent with the findings of Blumberg and colleagues (14, 16, 18) with chicken embryo fibroblasts and mouse brain and skin, and of Shoyab and Todaro and others (15, 17) with a variety of normal and transformed avian and mammalian cells. The  $K_d$  calculated from the binding data were similar for all four blood cell types. While the  $K_d$  remained relatively constant, the calculated number of binding sites per cell was more variable for an individual cell type in different experiments and between cell types in the same experiment. The causes of this larger variability are not known. The smaller number of binding sites in platelets is consistent with their smaller size.

The absence of specific binding of [ $^3$ H]PDBu to mature erythrocytes appears to be a unique finding among numerous mammalian and avian cell types. It is important in this regard that platelets, cells also lack-




FIGURE 7 H<sub>2</sub>O<sub>2</sub> production by PMN (A) and monocytes (B) stimulated by PHR( $\blacktriangle$ ), PDA( $\circ$ ), PDBu( $\square$ ), PMA( $\bullet$ ), and MZ( $\Delta$ ). All points represent the mean of triplicates  $\pm$  1 SEM. This data is representative of three comparable experiments.

ing a nucleus, have specific receptors for the phorbol esters, and chicken erythrocytes, which are nucleated, show no specific binding of [ $^3\text{H}$ ]PDBu (data not shown). Nagle and Blumberg (30) showed that enucleated fibroblasts (like control fibroblasts) displayed morphological changes in response to phorbol diesters. In addition, studies by Dunphy et al. (18), looking at the subcellular localization of [ $^3\text{H}$ ]PDBu binding in mouse brain, indicate that the principal site of binding is not the nucleus in that system. All of these factors support the idea that the lack of specific binding of phorbol esters to human erythrocyte is not on the basis of its enucleate state.

The specificity of [ $^3\text{H}$ ]PDBu binding to the blood cells studied here was demonstrated by experiments that showed that the biologically active compounds PMA, PDBu, MZ, and PDA inhibited binding while the biologically inactive compounds 4 $\alpha$ -PHR and PHR did not. The relative abilities of these compounds to inhibit binding, as shown by the calculated  $K_i$ , paralleled the relative order of their tumor-promoting activities in vivo. In general, the  $K_d$  for [ $^3\text{H}$ ]PDBu binding correlated well with the ED<sub>50</sub> for the various measured functional responses in all the blood cells examined. This is consistent with the concept that the magnitude of these biological responses is directly proportional in a continuous manner for a given cell to occupancy of receptors by the ligand. That is, one would expect a 50% maximal response when 50% of the cellular receptors were occupied by the ligand or when the concentration of free ligand added equaled the  $K_d$  for the receptor. Alternatively, as recently suggested for PMA stimulation of PMN  $\text{H}_2\text{O}_2$  production (31), individual cells could be triggered in an all or none fashion to produce a biological response, with a 50% maximal response occurring when 50% of the total cells were activated. Our data, which are based on responses of populations of cells, does not allow us to discriminate between these two interpretations.

The existence of high affinity receptors for the phor-

TABLE III  
ED<sub>50</sub> for  $\text{H}_2\text{O}_2$  Production Stimulated by  
Phorbol-related Compounds

Compound	ED <sub>50</sub>	
	Monocytes	Lymphocytes
PMA	13 nM	4 nM
PDBu	42 nM	42 nM
MZ	20 nM	20 nM
PDA	850 nM	780 nM
PHR	•	•
4 $\alpha$ -PHR	•	•

• No stimulation noted.




FIGURE 8 [ $^3\text{H}$ ]5HT release by platelets in response to phorbol-related compounds. Percent serotonin release was calculated as [(counts per minute in sample supernatant - counts per minute in blank supernatant) ÷ (counts per minute in lysate - counts per minute blank supernatant)] × 100. All points represent the mean of triplicates ± 1 SEM. This experiment is representative of three comparable experiments.  $\Delta$ , PMA (nM);  $\square$ , PDBu;  $\bullet$ , PHR and 4 $\alpha$  PHR ( $\mu\text{M}$ ).

bol diesters on a variety of animal cells implies the existence of an endogenous ligand for this receptor. Horowitz and Weinstein (32) reported the presence of a factor in serum and tissue extracts that inhibited [ $^3\text{H}$ ]PDBu binding to cells. Attempts to isolate and characterize such a ligand that would compete for binding to the receptor with [ $^3\text{H}$ ]PDBu and induce comparable cellular effects have not been successful thus far, due in part to the existence of phorbol ester-binding proteins (27) and hydrolases (33), which complicate the search. The many different responses elicited in different normal and leukemic blood cells (3-13, 34, 35) by the phorbol diester ligand-receptor interaction suggests that an endogenous ligand could be responsible for some of the physiologic and pathologic functions noted in these cells. A nontoxic, endogenous ligand for this receptor might have use in experimentally manipulating blood cell function and differentiation [use, e.g., in the experimental treatment of leukemia (35)].

## ACKNOWLEDGMENTS

We thank Dr. Gilbert White for advice on platelet procedures, Mary Naramore and Darrell Capel for technical assistance, Don Powell and John Mangan for art work, and Vera Lewis for typing.

This work was supported by the Veterans Administration, Washington, DC, and by grant 27070, awarded by the National Cancer Institute, Department of Health, Education, and Welfare.

## REFERENCES

1. Berenblum, I. 1941. The mechanism of carcinogenesis. A study of the significance of cocarcinogenic action and related phenomena. *Cancer Res.* 1: 807-814.



2. Diamond, L., T. G. O'Brien, and W. M. Baird. 1980. Tumor promoters and the mechanism of tumor promotion. *Adv. Cancer Res.* **32**: 1-74.
3. Blumberg, P. M. 1980. *In vitro* studies on the mode of action of the phorbol esters, potent tumor promoters: part 1. *C.R.C. Crit. Rev. Toxicol.* **8**: 153-197.
4. Blumberg, P. M. 1981. *In vitro* studies on the mode of action of the phorbol esters, potent tumor promoters: part 2. *C.R.C. Crit. Rev. Toxicol.* **8**: 199-234.
5. Pegoraro, L., J. Abrahm, R. A. Copper, A. Lewis, B. Lange, P. Meo, and G. Rovera. 1980. Differentiation of human leukemias in response to 12-*O*-tetradecanoyl-phorbol-13-acetate *in vitro*. *Blood*. **55**: 859-862.
6. Koeffler, H. P., M. Bar-Eli, and M. Territo. 1980. Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia. *J. Clin. Invest.* **66**: 1101-1108.
7. DeChatelet, L. R., P. S. Shirley, and R. B. Johnston. 1976. Effect of phorbol myristate acetate on the oxidative metabolism of human polymorphonuclear leukocytes. *Blood*. **47**: 545-554.
8. Lehrer, R. I., and L. Cohen. 1981. Receptor-mediated regulation of superoxide production in human neutrophils stimulated by phorbol myristate acetate. *J. Clin. Invest.* **68**: 1314-1320.
9. Nakagawara, A., C. F. Nathan, and Z. A. Cohn. 1981. Hydrogen peroxide metabolism in human monocytes during differentiation *in vitro*. *J. Clin. Invest.* **68**: 1243-1252.
10. White, J. G., G. H. R. Rao, and R. D. Estensen. 1974. Investigation of the release reaction in platelets exposed to phorbol myristate acetate. *Am. J. Pathol.* **75**: 301-314.
11. Zucker, M. B., W. Troll, and S. Belman. 1974. The tumor-promoter phorbol ester (12-*O*-tetradecanoyl-phorbol-13-acetate), a potent aggregating agent for blood platelets. *J. Cell Biol.* **60**: 325-336.
12. Touraine, J. L., J. W. Hadden, F. Touraine, E. M. Hadden, R. Estensen, and R. A. Good. 1977. Phorbol myristate acetate: a mitogen selective for a T-lymphocyte subpopulation. *J. Exp. Med.* **145**: 460-465.
13. Abb, J., G. J. Bayliss, and F. Deinhardt. 1979. Lymphocyte activation by the tumor-promoting agent 12-*O*-tetradecanoyl phorbol-13-acetate (TPA). *J. Immunol.* **122**: 1639-1642.
14. Driedger, P. E., and P. M. Blumberg. 1980. Specific binding of phorbol ester tumor promoters. *Proc. Natl. Acad. Sci. USA*. **77**: 567-571.
15. Shoyab, M., and G. J. Todaro. 1980. Specific high affinity cell membrane receptors for biologically active phorbol and ingenol esters. *Nature (Lond.)*. **288**: 451-455.
16. Delclos, K. B., D. S. Nagle, and P. M. Blumberg. 1980. Specific binding of phorbol ester tumor promoters to mouse skin. *Cell*. **19**: 1025-1032.
17. Sando, J. J., M. L. Hilfikir, D. S. Salomon, and J. J. Farrar. 1981. Specific receptors for phorbol esters in lymphoid cell populations: role in enhanced production of T-cell growth factor. *Proc. Natl. Acad. Sci. USA*. **78**: 1189-1193.
18. Dunphy, W. G., K. B. Delclos, and P. M. Blumberg. 1980. Characterization of specific binding of [<sup>3</sup>H]phorbol 12,13-dibutyrate and [<sup>3</sup>H]phorbol 12-myristate 13-acetate to mouse brain. *Cancer Res.* **40**: 3635-3641.
19. Weinberg, J. B., J. J. Muscato, and J. E. Niedel. 1981. Monocyte chemotactic peptide receptor. Functional characteristics and ligand-induced regulation. *J. Clin. Invest.* **68**: 621-630.
20. Niedel, J., S. Wilkinson, and P. Cuatrecasas. 1979. Receptor-mediated uptake and degradation of <sup>125</sup>I-chemotactic peptide by human neutrophils. *J. Biol. Chem.* **254**: 10700-10706.
21. Tangen, O., H. J. Berman, and P. Marfey. 1971. Gel filtration—a new technique for separation of blood platelets from plasma. *Thromb. Diath. Haemorrh.* **25**: 268-278.
22. Jerushalmy, Z., and M. B. Zucker. 1966. Some effects of fibrinogen degradation products (FDP) on blood platelets. *Thromb. Diath. Haemorrh.* **15**: 413-419.
23. Pick, E., and D. Mizel. 1981. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. *J. Immunol. Meth.* **46**: 211-226.
24. Hecker, E. 1978. Structure-activity relationships in diterpene esters irritant and cocarcinogenic to mouse skin. In *Carcinogenesis. Mechanisms of Tumor Promotion and Cocarcinogenesis*. T. J. Slaga, A. Sivak, and R. K. Boutwell, editors. Raven Press, New York. **2**: 11-48.
25. Hecker, E. 1971. Isolation and characterization of the cocarcinogenic principles from croton oil. In *Methods in Cancer Research*. H. Busch, editor. Academic Press, Inc., New York. **6**: 439-484.
26. Cheng, Y., and W. H. Prusoff. 1973. Relationship between the inhibition constant (*K<sub>i</sub>*) and the concentration of inhibitor which causes 50 per cent inhibition (*I<sub>50</sub>*) of an enzymatic reaction. *Biochem. Pharmacol.* **22**: 3099-3108.
27. Shoyab, M., and G. J. Todaro. 1982. Partial purification and characterization of a binding protein for biologically active phorbol and ingenol esters from murine sera. *J. Biol. Chem.* **257**: 439-445.
28. Solanki, V., and T. J. Slaga. 1981. Specific binding of phorbol ester tumor promoters to intact primary epidermal cells from Sencar mice. *Proc. Natl. Acad. Sci. USA*. **78**: 2549-2553.
29. Solanki, V., T. J. Slaga, M. Callahan, and E. Huberman. 1981. Down regulation of specific binding of [20-<sup>3</sup>H] phorbol 12,13-dibutyrate and phorbol ester-induced differentiation of human promyelocytic leukemia cells. *Proc. Natl. Acad. Sci. USA*. **78**: 1722-1725.
30. Nagle, D. S., and P. M. Blumberg. 1980. Activity of phorbol ester tumor promoters on enucleated Swiss 3T3 cells. *Cancer Res.* **40**: 1066-1072.
31. Hafeman, D. G., H. M. McConnell, J. W. Gray, and P. N. Dean. 1982. Neutrophil activation monitored by flow cytometry: stimulation by phorbol diesters is an all-or-none event. *Science (Wash., DC)*. **215**: 673-675.
32. Horowitz, A. D., E. Greenebaum, and I. B. Weinstein. 1981. Identification of receptors for phorbol ester tumor promoters in intact mammalian cells and of an inhibitor of receptor binding in biologic fluids. *Proc. Natl. Acad. Sci. USA*. **78**: 2315-2319.
33. Shoyab, M., T. C. Warren, and G. J. Todaro. 1981. Isolation and characterization of an ester hydrolase active on phorbol diesters from murine liver. *J. Biol. Chem.* **256**: 12529-12534.
34. Rovera, G., D. Santoli, and C. Damsky. 1979. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. *Proc. Natl. Acad. Sci. USA*. **76**: 2779-2783.
35. Weinberg, J. B. 1981. Tumor cell killing by phorbol ester-differentiated human leukemia cells. *Science (Wash., DC)*. **213**: 655-657.